KRKatharina Raba

Katharina Raba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katharina Raba has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A human NK cell progenitor that originates in the thymus and generates KIR + NKG2A − NK cells

    by Julian Reiß, Sujal Ghosh, Michael Scheid, Lea Graafen, Nadine Scherenschlich, Sandra Weinhold, Katharina Raba, Stefan Paulusch, Elena De Dominico, Thi X. U. Pham, et al.

    KIR + NKG2A − natural killer (NK) cells have the unique ability to detect down-regulation of single HLA-I allotypes, frequently occurring in malignantly transformed and virus-infected cells. We have recently shown that circulating innate lymphoid cells 1 (cILC1s) have the potential to generate such KIR + NKG2A − NK cells, but their developmental origin was unknown. Here, we demonstrate that the development of cILC1 is thymus dependent and identify a putative progenitor of cILC1s in the thymus (thyILC1). Single-cell RNA sequencing analysis revealed a close relationship of thyILC1s to CD34 + double-negative thymocytes. Both generated comparable NK cell frequencies, while only thyILC1s could be efficiently differentiated into KIR + NKG2A − NK cells. Last, patients with FOXN1 haploinsufficiency, showing congenital thymic hypoplasia, exhibited a profound deficiency of cILC1s but not cILC2s and cILC3s, demonstrating their specific thymus dependency. Together, the data suggest that thyILC1s are the source of a thymus-dependent NK cell differentiation pathway that promotes generation of KIR + NKG2A − NK cells.


  • Open Access

    Serum-free differentiation platform for the generation of B lymphocytes and natural killer cells from human CD34+ cord blood progenitors

    by Rigveda Bhave, Carla-Johanna Kath, Nadine Rüchel, Eleni Vasileiou, Vera H. Jepsen, Katharina Raba, Aleksandra A. Pandyra, Ute Fischer, Gesine Kogler

    Introduction Pre-clinical research on B and NK cell development relies on traditional murine stromal cell-based systems with reduced physiological relevance and clinical applicability. Methods A serum-free, fully humanized co-culture system utilizing human bone marrow-derived mesenchymal stromal cells (BM-MSCs) was developed to differentiate CB-CD34+ cells towards B and NK cell lineages. Differentiation dynamics were monitored via flow cytometry, with immunophenotypic analysis tracking progression from progenitors to mature cells. Results The system generated CD19+IgM+ immature B cells and CD56+CD16+ NK cells, recapitulating fetal stages of human lymphopoiesis. Serum-free media conditions ensured reproducibility and high overall yield of B and NK cell progenitors. Flow cytometry identified distinct population peaks, confirming temporal control over differentiation. Conclusion This clinically relevant platform addresses the limitations of traditional models by providing a more physiologically accurate human microenvironment. The serum-free system supports applications in disease modeling, genotoxic compound screening, and mutational studies of hematopoiesis. By enabling scalable production of B and NK cells it aims to accelerate translational research for immunodeficiencies, cancer immunotherapy, and hematopoietic disorders. Significance Statement This article presents a novel, fully humanized, serum-free co-culture system that efficiently directs cord blood-derived hematopoietic stem cells into B and natural killer (NK) cells. By using human bone marrow stromal cells and recombinant human cytokines, it overcomes the limitations of murine-based models and better mimics human blood cell development. This platform enables improved disease modeling and therapeutic testing relevant to human hematopoiesis.


  • Open Access

    DNA Damage Response After Treatment of Cycling and Quiescent Cord Blood Hematopoietic Stem Cells With Distinct Genotoxic Noxae

    by Fabienne Becker, Meryem Ouzin, Stefanie Liedtke, Katharina Raba, Gesine Kogler

    Hematopoietic stem cells (HSC) from cord blood can be applied as an alternative to bone marrow in transplantation to treat hematological diseases. Umbilical cord blood (UCB) consists of cycling and non-cycling CD34+/CD45low cells needed for long-term and short-term engraftment. After sorting and subsequent in vitro culture, quiescent HSCs enter the cell cycle. This enables the analysis of HSCs in 2 different cell cycle stages and the comparison of their responses to different genotoxic noxae. To analyze different mechanisms of DNA damage induction in cells, 2 different genotoxins were compared: etoposide, a topoisomerase II inhibitor that targets mitosis in the S/G2-phase of the cell cycle and the alkylating nitrosamine N-Nitroso-N-methylurea (MNU), which leads to the formation of methyl DNA adducts resulting in DNA double breaks during DNA replication and persistent mutations. Cycling cells recovered after treatment even with higher concentrations of etoposide (1.5µM/ 5µM/10µM), while sorted cells treated with MNU (0.1mM/0.3mM/0.5mM/1mM/3Mm/ 5mM) recovered after treatment with the lower MNU concentrations whereas high MNU concentrations resulted in apoptosis activation. Quiescent cells were not affected by etoposide treatment showing no damage upon entry into the cell cycle. Treatment with MNU, similarly to the cycling cells, resulted in a dose-dependent cell death. In conclusion, we found that depending on the genotoxic trigger and the cycling status, CD34+cells have distinct responses to DNA damage. Cycling cells employ both DDR and apoptosis mechanisms to prevent damage accumulation. Quiescent cells predominantly undergo apoptosis upon damage, but their cell cycle status protects them from certain genotoxic insults.


  • Open Access

    Uptake dynamics of graphene quantum dots into primary human blood cells following in vitro exposure

    by Stefan Fasbender, Sonja Allani, Christian Wimmenauer, Ron-Patrick Cadeddu, Katharina Raba, Johannes C. Fischer, Bekir Bulat, Martina Luysberg, Claus A. M. Seidel, Thomas Heinzel, et al.

    Human leukocytes obtained from samples of leukapheresis products of three healthy donors stimulated by granulocyte colony stimulating factor (G-CSF) were exposed to graphene quantum dots. A time- and concentration dependent uptake was observed with a significantly greater uptake into monocytes and granulocytes in comparison to lymphocytes, suggesting a better incorporation ability of cells with phagocytotic properties. The uptake rates also correlate with the cell membrane area. Looking at the different lymphoid subsets a greater uptake was found into CD19+ B-, CD56+ natural killer cells and CD34+ hematopoietic stem cells (HSC) in comparison to CD4+ T- and CD8+ T cells. Independent of the cell type studied, the observed uptake dynamics is consistent with a diffusion-driven process, which allows the determination of cell-specific membrane permeabilities for the graphene quantum dots. The toxicity of the quantum dots is relatively low resulting in a 90% viability of the entire leukocyte population after 36 hours of exposure to GQDs at a concentration of 500 μg ml−1.


  • Genomic high resolution profiling of single CK+/CD45- CTCspurified by flow sorting fromclinical CellSearch samples

    by R Neves, K Raba, O Schmidt, E Honisch, F Meier-Stiegen, B Behrens, B Möhlendick, T Fehm, H Neubauer, Ca Klein, et al.

    Circulating tumour cells (CTCs) detected by CellSearchTM are important prognostic markers. To learn more about their biology and to use CTCs for clinical applications in sense of a liquid biopsy, we established and tested a workflow for purification of CTCs from CellSearchTM cartridges using a flow sorting approach and that allows their subsequent high-resolution genomic profiling. 34 CellSearchTM pre-processed breast cancer clinical samples were used for single CTCs sorting in a MoFlo sorter. Genome of single CTCs was amplified using an MseI adapter-linker-based PCR. Amplification products were analysed by high-resolution array-based comparative genomic hybridization (aCGH); gene specific real-time PCR based assay to confirm CyclinD1 locus amplification; and genomic sequencing to screen mutations in exon 20 of PIK3CA gene. A flow sorting protocol was appropriate to the analysis of almost 90% of the cartridges tested. The number of CTCs detected by flow cytometry correlated well with those detected by CellSearchTM. The genome of 72.9% of the sorted single CTCs could be amplified. In over 95% of the cells chromosomal aberrations typically observed in metastatic breast cancers were detected and results for CCND1 locus were validated by real-time PCR. Typical mutations in exon 20 of PIK3CA gene in cells isolated from two patients were detected. We present a workflow to isolate CTCs from clinical CellSearchTM samples enabling their subsequent genomic profiling using array CGH. Our data give an impression on the genomic makeup of CTCs from metastasized breast cancer patients at high-resolution and might significantly facilitate their further molecular characterization.

  • Effect of leukapheresis on efficient CTC enrichment for comprehensive molecular characterization and clinical diagnostics.

    by Nikolas H. Stoecklein, Dieter Niederacher, Stefan A. Topp, Luisa Zacarias Föhrding, Christian Vay, Wolfram Trudo Knoefel, Nikola S. Kasprowicz, Philip Gm Hepp, Svjetlana Mohrmann, Wolfgang Janni, et al.

    E21020 Background: Circulating tumor cells (CTCs) are promising biomarkers for diagnosis and systemic therapy. However, their infrequent detection rates limit currently their clinical use. Here we tested whether leukapheresis could be a suitable method to increase CTC yields and detection rates by increasing dramatically the analyzed blood volume. Methods: We screened 3x106 PBMNCs of 48 historical leukapheresis products harvested from 24 breast cancer patients in the setting of high-dose chemotherapy and from a non-cancer control group (n=10), respectively, with a standard immuno-assay using an anti-cytokeratin antibody (A45/BB3) to detect CTCs. Detected CTCs were isolated, their genomic DNA amplified, and the whole genome screened for chromosomal aberrations using comparative genomic hybridization (CGH) (n=48). To validate the CTC detection frequencies in leukapheresis products, we initiated a prospective pilot-study and performed leukapheresis in 13 cancer patients (breast and pancreatic cancer). 1 mL of the leukapheresis product (total volume: up to 150 ml) was analyzed using the CellSearch® system as well as 7.5 ml peripheral blood taken from the same patients. Results: 44/48 (91.7%) of leukapheresis samples contained CTCs with a median count of 3.0 in 3x106 PBMNC (range: 1-35 CTCs). None of the 10 analyzed healthy controls displayed CTCs. We successfully performed single cell CGH of 48 CTCs from 19 patients revealing aberrant CGH profiles in 56% with gains and losses typical for breast cancer. Interestingly, CTCs with high aberration numbers were associated with early metastatic relapse. The validation study using CellSearch® in 13 cancer patients demonstrated in leukapheresis products significantly higher CTC detection frequencies (13/13 vs. 5/13) and CTC numbers (median: 13, range: 1-51 vs. median 0, range: 0-7; p<0.001) compared to the matched peripheral blood samples. Conclusions: Our results indicated that leukapheresis provides CTC detection rates and yields at unprecedented scale. Thus we believe, that leukapheresis will help to exploit the full clinical potential of CTCs as biomarkers for diagnosis and systemic therapy.